What is HC Wainwright’s Estimate for ESPR Q1 Earnings?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, March 4th. HC Wainwright analyst J. Pantginis expects that the biopharmaceutical company will earn ($0.16) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ Q2 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.01) EPS.

Several other equities research analysts also recently issued reports on the stock. JMP Securities reiterated a “market outperform” rating and set a $4.00 price objective (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a research note on Friday, December 13th. The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective for the company. Cantor Fitzgerald assumed coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price on the stock. Finally, StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Esperion Therapeutics currently has an average rating of “Hold” and a consensus price target of $6.75.

Esperion Therapeutics Price Performance

Esperion Therapeutics stock opened at $1.65 on Thursday. The company has a market cap of $325.11 million, a price-to-earnings ratio of -2.58 and a beta of 1.01. Esperion Therapeutics has a 12 month low of $1.57 and a 12 month high of $3.94. The stock’s 50-day moving average is $1.99 and its 200-day moving average is $2.09.

Institutional Investors Weigh In On Esperion Therapeutics

Several institutional investors have recently bought and sold shares of ESPR. Cibc World Markets Corp bought a new stake in Esperion Therapeutics during the fourth quarter worth approximately $39,000. Versor Investments LP acquired a new position in shares of Esperion Therapeutics in the 3rd quarter worth approximately $44,000. SJS Investment Consulting Inc. acquired a new position in shares of Esperion Therapeutics in the 4th quarter worth approximately $55,000. Crestline Management LP bought a new stake in shares of Esperion Therapeutics in the 4th quarter worth approximately $63,000. Finally, Summit Wealth Group LLC bought a new position in shares of Esperion Therapeutics in the third quarter valued at $66,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.